Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial-Reference-Cited by-同舟云学术

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial

Published:2023-07 Issue:4 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Laurent Sarah A.¹,Strauli Nicolas B.¹,Eggers Erica L.¹,Wu Hao¹^ORCID,Michel Brady¹,Demuth Stanislas¹,Palanichamy Arumugam¹,Wilson Michael R.¹^ORCID,Sirota Marina¹,Hernandez Ryan D.¹^ORCID,Cree Bruce Anthony Campbell¹^ORCID,Herman Ann E.¹,von Büdingen H.-Christian¹

Affiliation:

1. From the Department of Neurology (S.A.L., E.L.E., H.W., B.M., S.D., A.P., M.R.W., B.A.C.C., H.-C.B.), Weill Institute for Neurosciences; Biomedical Sciences Graduate Program (N.B.S.); Bakar Computational Health Sciences Institute and Department of Pediatrics (M.S.); Department of Bioengineering and Therapeutic Sciences (R.D.H.), University of California, San Francisco, CA; Department of Human Genetics (R.D.H.), McGill University, Montreal, QC, Canada; and OMNI Biomarker Development (A.E.H.),...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200118

Reference45 articles.

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

2. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

3. Reassessing B cell contributions in multiple sclerosis

4. B-cell Therapy for Multiple Sclerosis: Entering an era

5. Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 ⁺ T-Cell Proliferation in Patients With Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-07

2. B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases;Clinical Reviews in Allergy & Immunology;2024-03-09

3. Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets;Annals of Clinical and Translational Neurology;2024-01-10

4. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis;Journal of Neuroinflammation;2023-09-26